John Boyce

Weve experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, Precede Bio developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.

Valora Therapeutics Inc. (Valora) is a pre-clinical stage biopharmaceutical company based in San Diego, California, USA, pioneering a new biologic platform invented by Nobel Laureate Dr. Carolyn Bertozzi (Stanford). Our proprietary platform technology enables the engineering of chimeric antibodies to unlock new mechanisms of immune signaling and activity, paving the way for transformative therapies in oncology, immune diseases, and beyond.

Weve experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, Precede Bio developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.

About 28 Capita (Formerly known as Tiger Gene, which was seeded by Tiger Management) We specialize in unlocking high-potential technologies trapped in academia, partnering with leading scientists and institutions to turn cutting-edge research into breakthrough therapies 28 Capital is a life sciences venture fund dedicated to creating and building the next generation of transformative biotech companies. Through our unique investment model, we not only provide capital—we roll up our sleeves to help found, fund, and scale companies from day one. Our team brings deep scientific and operational expertise, helping entrepreneurs advance from concept to clinic with speed, precision, and purpose. At the heart of our work is a singular mission: to help founders realize their boldest visions and bring life-changing innovations to patients who need them most. At 28 Capital, we don’t just invest—we build.

Valora Therapeutics Inc. (Valora) is a pre-clinical stage biopharmaceutical company based in San Diego, California, USA, pioneering a new biologic platform invented by Nobel Laureate Dr. Carolyn Bertozzi (Stanford). Our proprietary platform technology enables the engineering of chimeric antibodies to unlock new mechanisms of immune signaling and activity, paving the way for transformative therapies in oncology, immune diseases, and beyond.

Next generation protein interrogation powered by nanoneedles, enabling early disease detection, prognostic monitoring and biomarker discovery on a single chip.